**Dual-Phase Medium-Chain Triglyceride Intervention Hypothesis**
**Core Mechanism:**
Early-phase MCT administration (C8-C10) stimulates astrocytic ketogenesis while inhibiting mitochondrial glucose oxidation, forcing metabolic flexibility. Late-phase shorter MCTs (C6-C8) maintain ketone production without excessive mitochondrial stress. This sequential approach targets the temporal evolution of metabolic dysfunction in neurodegeneration, acknowledging that metabolic impairment is not static but
**Background and Rationale** TREM2 variants represent major genetic risk factors for Alzheimer's disease, with loss-of-function mutations increasing dementia risk threefold. While TREM2 is exclusively expressed on microglia, emerging evidence suggests its primary pathogenic role occurs through disrupted astrocyte-microglia communication rather than intrinsic microglial dysfunction. Healthy brain homeostasis depends on coordinated responses between these glial populations, where TREM2+ microglia
Verdict Summary
5/10
dimensions won
Dual-Phase Medium-Chain Triglyceride Int
6/10
dimensions won
TREM2-Dependent Astrocyte-Microglia Cros
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.75
0.88
Evidence
0.70
0.80
Novelty
0.65
0.72
Feasibility
0.85
0.82
Impact
0.70
0.78
Druggability
0.90
0.65
Safety
0.85
0.58
Competition
0.75
0.70
Data
0.80
0.85
Reproducible
0.75
0.75
Score Breakdown
Dimension
Dual-Phase Medium-Chain Trigly
TREM2-Dependent Astrocyte-Micr
Mechanistic
0.750
0.880
Evidence
0.700
0.800
Novelty
0.650
0.720
Feasibility
0.850
0.820
Impact
0.700
0.780
Druggability
0.900
0.650
Safety
0.850
0.580
Competition
0.750
0.700
Data
0.800
0.850
Reproducible
0.750
0.750
Evidence
Dual-Phase Medium-Chain Triglyceride Intervention
No evidence citations yet
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
No evidence citations yet
Debate Excerpts
Dual-Phase Medium-Chain Triglyceride Intervention
4 rounds · quality: 0.93
Theorist
Based on the glial ketone shunt hypothesis and astrocyte-neuron metabolic interactions in neurodegeneration, here are 7 novel therapeutic hypotheses:
## Hypothesis 1: Temporal Metabolic Window Therap...
Skeptic
**Strong Counter-evidence**: PMID:37686202 and others show lactate is neuroprotective and essential for brain function, not harmful. The astrocyte-neuron lactate shuttle is a well-established neuropro...
Domain Expert
Based on my analysis of the hypotheses and the available data, here's my practical feasibility assessment:
## FEASIBILITY ASSESSMENT
### **Hypothesis 1: Temporal Metabolic Window Therapy (HMGCS2 tar...
Based on my research, I'll now generate novel therapeutic hypotheses focused on aging-related gene expression changes that predict neurodegenerative vulnerability. Here are 6 evidence-based therapeuti...
Skeptic
## Critical Evaluation of Therapeutic Hypotheses
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and counter-evidence:
### 1. **AP1S1-Mediated Vesicular Transport Restora...
Domain Expert
# Practical Feasibility Assessment of Therapeutic Hypotheses
Based on my analysis of druggability, existing compounds, competitive landscape, and development considerations, here's my comprehensive a...
Synthesizer
Based on my synthesis of the Theorist's hypotheses, Skeptic's critiques, and Expert's feasibility assessment, here's the final JSON output:
```json
{
"ranked_hypotheses": [
{
"rank": 1,
...